CLINICAL ROLE -
Medical experts detail the current and evolving roles of BTK inhibitors in treatment of patients with relapsed/refractory mantle cell lymphoma.
EP. 1: Defining Oncologic Traits Unique To Mantle Cell Lymphoma
Dr Haumschild, PharmD, MS, MBA leads a panel of experts identifying characteristics unique to MCL and addressing initial treatment strategies.
EP. 2: Exploring The Changing Landscape in MCL Treatment
Drs Preetesh Jain and Michael Wang exchange insights regarding the current and prospective treatment options for patients with Mantle Cell Lymphoma.
EP. 3: Addressing Unmet Needs in The Relapse/Refractory Setting
Preetesh Jain, MBBS, MD, DM, PhD, offers perspective on unmet needs in treatment of patients with relapsed/refractory mantle cell lymphoma.
EP. 4: Key Comorbidity Considerations for Patients With MCL
Ryan Haumschild, PharmD, MS, MBA, leads a discussion regarding the treatment of relapsed/refractory mantle cell lymphoma in the presence of comorbidities.
EP. 5: Utilizing BTK Inhibitors to Achieve Chemo-Free Therapy
This panel of experts navigates the effects of BTK inhibitors, and their impact on trpatients with Mantle Cell Lymphoma.
EP. 6: Optimizing The Impact of BTK Inhibitors
Drs Haumschild, Jain, and Wang discuss clinical pearls regarding BTK inhibitors, including drug interactions.
EP. 7: Understanding The Prevalence of Mutations in Treatment of MCL
Drs Jain and Wang discuss concerns regarding mutations in the treatment setting for patients with mantle cell lymphoma.
EP. 8: Toxicity Management of BTK Inhibitors
Experts navigate MCL drug interactions, including those between BTK inhibitors with common anticoagulants and antifungals.
EP. 9: Roles Of Pharmacists In The Management Of MCL
Ryan Haumschild, PharmD, MS, MBA, enlightens the panel on the unique roles of pharmacists in treatment management for patients with mantle cell lymphoma.
EP. 10: Developing an Optimal Treatment Pathway for Patients With MCL
The experts discuss their decision-making process in selecting treatment for patients with mantle cell lymphoma.
EP. 11: Aligning Value-Based Care with Payer Considerations In MCL Therapy Management
Key opinion leaders evaluate treatment options for MCL while emphasizing payer considerations.
EP. 12: Pipeline Treatments for Patients With MCL
Drs Haumschild, Jain, and Wang evaluate MCL therapies under investigation and the impact on the future of MCL treatment.
EP. 13: Future Direction and Unmet Needs in Treatment of Mantle Cell Lymphoma
The experts provide their closing thoughts and discuss unmet needs in the treatment of patients with MCL.
2 Commerce Drive Cranbury, NJ 08512